(QGEN) Qiagen - Ratings and Ratios
Kits, Assays, Instruments, Software, Services
QGEN EPS (Earnings per Share)
QGEN Revenue
Description: QGEN Qiagen
Qiagen NV is a leading provider of sample-to-insight solutions, transforming biological samples into molecular insights. The company offers a broad range of products and services, including consumables, instruments, and software, catering to various markets such as molecular diagnostics, academia, pharmaceutical, and applied testing.
From a business perspective, Qiagens product portfolio is diversified across multiple categories, including primary and secondary sample technology consumables, immune response consumables, oncology and sexual and reproductive health consumables, and sample-to-insight instruments. This diversification provides a stable revenue stream and opportunities for growth. Key Performance Indicators (KPIs) to monitor Qiagens performance include revenue growth, gross margin, operating margin, and return on equity (ROE). Currently, Qiagens ROE is 2.69%, indicating room for improvement.
To further analyze Qiagens financial health, other relevant KPIs include debt-to-equity ratio, interest coverage ratio, and cash conversion cycle. These metrics can provide insights into the companys capital structure, ability to meet interest payments, and working capital management. Additionally, monitoring Qiagens research and development (R&D) expenses as a percentage of revenue can help assess the companys commitment to innovation and its potential for future growth.
Qiagens customer base is diverse, serving various industries, including molecular diagnostics, academia, pharmaceutical, and applied testing. The companys software-as-a-service offering is also a notable aspect of its business, providing recurring revenue and opportunities for upselling and cross-selling. As a Trading Analyst, it is essential to monitor Qiagens customer acquisition and retention rates, as well as its pricing strategy, to understand the companys competitive positioning and revenue trajectory.
QGEN Stock Overview
| Market Cap in USD | 10,044m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1996-06-28 |
QGEN Stock Ratings
| Growth Rating | 21.8% |
| Fundamental | 68.2% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -2.88% |
| Analyst Rating | 3.94 of 5 |
QGEN Dividends
| Dividend Yield 12m | 3.18% |
| Yield on Cost 5y | 3.08% |
| Annual Growth 5y | % |
| Payout Consistency | 8.8% |
| Payout Ratio | 64.3% |
QGEN Growth Ratios
| Growth Correlation 3m | -76.5% |
| Growth Correlation 12m | 65% |
| Growth Correlation 5y | -45.8% |
| CAGR 5y | 4.21% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.14 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.39 |
| Sharpe Ratio 12m | -0.17 |
| Alpha | 1.30 |
| Beta | 0.658 |
| Volatility | 20.38% |
| Current Volume | 653.1k |
| Average Volume 20d | 1069.7k |
| Stop Loss | 46 (-3.2%) |
| Signal | 0.70 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (373.4m TTM) > 0 and > 6% of Revenue (6% = 122.4m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 33.86% (prev 40.97%; Δ -7.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 675.0m > Net Income 373.4m (YES >=105%, WARN >=100%) |
| Net Debt (710.2m) to EBITDA (715.1m) ratio: 0.99 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (218.2m) change vs 12m ago -1.71% (target <= -2.0% for YES) |
| Gross Margin 62.97% (prev 48.44%; Δ 14.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 35.76% (prev 34.74%; Δ 1.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.02 (EBITDA TTM 715.1m / Interest Expense TTM 37.5m) >= 6 (WARN >= 3) |
Altman Z'' 3.77
| (A) 0.12 = (Total Current Assets 1.82b - Total Current Liabilities 1.13b) / Total Assets 5.82b |
| (B) 0.43 = Retained Earnings (Balance) 2.52b / Total Assets 5.82b |
| (C) 0.09 = EBIT TTM 526.2m / Avg Total Assets 5.70b |
| (D) 0.92 = Book Value of Equity 2.13b / Total Liabilities 2.32b |
| Total Rating: 3.77 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.24
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 4.71% = 2.36 |
| 3. FCF Margin 24.33% = 6.08 |
| 4. Debt/Equity 0.41 = 2.42 |
| 5. Debt/Ebitda 0.99 = 1.78 |
| 6. ROIC - WACC (= 0.49)% = 0.61 |
| 7. RoE 10.66% = 0.89 |
| 8. Rev. Trend 32.99% = 2.47 |
| 9. EPS Trend -37.36% = -1.87 |
What is the price of QGEN shares?
Over the past week, the price has changed by +1.50%, over one month by +4.65%, over three months by -1.62% and over the past year by +11.41%.
Is Qiagen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QGEN is around 42.99 USD . This means that QGEN is currently overvalued and has a potential downside of -9.49%.
Is QGEN a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.8 | 9% |
| Analysts Target Price | 51.8 | 9% |
| ValueRay Target Price | 47.5 | -0% |
Last update: 2025-10-03 13:20
QGEN Fundamental Data Overview
P/E Trailing = 27.3609
P/E Forward = 16.9779
P/S = 4.9233
P/B = 2.8652
P/EG = 0.3205
Beta = 0.658
Revenue TTM = 2.04b USD
EBIT TTM = 526.2m USD
EBITDA TTM = 715.1m USD
Long Term Debt = 884.8m USD (from longTermDebt, last quarter)
Short Term Debt = 559.2m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 710.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.53b USD (10.04b + Debt 1.44b - CCE 953.8m)
Interest Coverage Ratio = 14.02 (Ebit TTM 526.2m / Interest Expense TTM 37.5m)
FCF Yield = 4.71% (FCF TTM 496.3m / Enterprise Value 10.53b)
FCF Margin = 24.33% (FCF TTM 496.3m / Revenue TTM 2.04b)
Net Margin = 18.30% (Net Income TTM 373.4m / Revenue TTM 2.04b)
Gross Margin = 62.97% ((Revenue TTM 2.04b - Cost of Revenue TTM 755.5m) / Revenue TTM)
Gross Margin QoQ = 62.65% (prev 63.85%)
Tobins Q-Ratio = 1.81 (Enterprise Value 10.53b / Total Assets 5.82b)
Interest Expense / Debt = 0.53% (Interest Expense 7.61m / Debt 1.44b)
Taxrate = 24.11% (30.6m / 126.8m)
NOPAT = 399.4m (EBIT 526.2m * (1 - 24.11%))
Current Ratio = 1.61 (Total Current Assets 1.82b / Total Current Liabilities 1.13b)
Debt / Equity = 0.41 (Debt 1.44b / totalStockholderEquity, last quarter 3.51b)
Debt / EBITDA = 0.99 (Net Debt 710.2m / EBITDA 715.1m)
Debt / FCF = 1.43 (Net Debt 710.2m / FCF TTM 496.3m)
Total Stockholder Equity = 3.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.41% (Net Income 373.4m / Total Assets 5.82b)
RoE = 10.66% (Net Income TTM 373.4m / Total Stockholder Equity 3.50b)
RoCE = 11.99% (EBIT 526.2m / Capital Employed (Equity 3.50b + L.T.Debt 884.8m))
RoIC = 7.92% (NOPAT 399.4m / Invested Capital 5.04b)
WACC = 7.43% (E(10.04b)/V(11.49b) * Re(8.44%) + D(1.44b)/V(11.49b) * Rd(0.53%) * (1-Tc(0.24)))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.27%
[DCF Debug] Terminal Value 78.62% ; FCFE base≈459.9m ; Y1≈519.5m ; Y5≈703.2m
Fair Price DCF = 52.08 (DCF Value 11.29b / Shares Outstanding 216.8m; 5y FCF grow 15.06% → 3.0% )
EPS Correlation: -37.36 | EPS CAGR: -58.31% | SUE: -4.0 | # QB: 0
Revenue Correlation: 32.99 | Revenue CAGR: 2.42% | SUE: 2.63 | # QB: 2
Additional Sources for QGEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle